Compare Adaptive Biotechnologies Corp (ADPT) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cardinal Health Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Cardinal Health Inc trades at $239.75 (market cap $55.88B). The key difference: Cardinal Health Inc is far larger — about 13.8× Adaptive Biotechnologies Corp's market cap, and Cardinal Health Inc pays a 0.86% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CAH | |
|---|---|---|
Market Cap | $4.04B | $55.88B |
Sector | Health | Health |
52-Week High | $25.45 | $240.26 |
52-Week Low | $12.30 | $146.04 |
Enterprise Value | $4.10B | $59.91B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.
Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
